Session 2: Maximizing the survival benefit through a sequential treatment strategy in locally advanced or metastatic urothelial cancer
Release date: 09-05-2024
Expiration date: 08-05-2025
The increasing availability of treatment options in the first-line (1L) setting after ESMO 2023 has led to a growing complexity in determining sequential treatment strategies for different clinical scenarios following progression of 1L therapies. In this educational program on 'Best Practice Exchange in Clinical Case Scenarios', field experts will discuss the latest evidence supporting the optimal utilization of sequential treatments, including immunotherapy, chemotherapy (CT), antibody-drug conjugates (ADCs), and targeted therapies, to prolong continuum of care and maximize survival benefits for patients. A better understanding of how to sequence available options for second-line (2L) and salvage treatments in routine patient care will facilitate optimal management of urothelial cancer patients.
This English program is available with subtitles in the following languages:
参与专家
Aristotelis Bamias 教授
雅典国立卡波季斯特里安大学
希腊雅典
Aristotelis Bamias是希腊雅典大学医学院的教授。他在雅典大学学习医学，并在英国伦敦的哈默史密斯医院、皇家马斯登医院和圣巴塞洛缪医院接受过内科学和肿瘤学培训。Bamias教授在雅典大学完成毕业论文，在伦敦大学获得PhD学位，致力于单克隆抗体在癌症诊断和治疗中的应用。他还曾在伦敦大学担任肿瘤内科讲师。他现在供职于希腊雅典大学内科第二预科、是阿提康大学医院的肿瘤学家，并于2019年至 2022年9月担任该科主任。
Bamias教授的主要研究方向是泌尿生殖系统和妇科肿瘤。 他曾担任希腊肿瘤学协作组 (HECOG) 泌尿生殖工作组的协调员10年，并担任HECOG 在欧洲妇科肿瘤试验网络协作组 (ENGOT) 的代表3年。Bamias教授是希腊生殖泌尿系统癌症组 (HGUCG) 的创始成员和主席。 他还是国际转移性肾细胞癌数据库联盟 (IMDC) 的成员，也是国际尿路上皮癌回顾性研究 (RISC) 的研究员。
Bamias教授是英国皇家内科医师学会 (MRCP, UK) 成员，也是ESMO、ASCO和欧洲妇科肿瘤学会 (ESGO) 的成员。 自2012 年以来，他一直是ESMO泌尿生殖系统癌症学院的成员，并于2016年至2020年担任该小组主席。自2016年以来，他一直是ESMO和EMUC大会科学委员会的成员，为大会邀请教员，并组织ESMO教育活动。 作为多个国际咨询委员会、国际试验指导委员会和共识专家组的成员，他领导了许多国内和国际的、行业赞助的和纯学术的研究，并在包括N Engl J Med、柳叶刀、柳叶刀肿瘤学和J Clin Oncol等同行评审期刊上发表了300多篇原创论文和评论。
Philippe Barthélémy, MD, PhD
Institute of Cancer in Strasbourg (ICANS)
Strasbourg, France
Philippe Barthélémy is a medical oncologist in the Department of Medical Oncology at the Institute of Cancer in Strasbourg (ICANS), France. He serves as the Head of the Genitourinary team and Clinical Research Committee and co-leads the Molecular Tumor Board at ICANS.
He completed his internship at the University Hospital of Strasbourg, France and obtained his Doctor of Medicine degree in 2009 and his thesis in molecular biology in 2016 from the University of Strasbourg. During his specialization in medical oncology, he received training in clinical development for new anticancer drugs at the Jules Bordet Institute in Brussels under Professor Ahmad Awada's supervision.
Dr. Barthélémy is currently serving as Principal Investigator (PI) and Sub-Investigator (SI) for over 50 ongoing trials while also having authored/co-authored numerous publications in recognized scientific journals. His primary research interest lies in developing new therapies for renal cell carcinoma and urothelial cancer. He is a member of ESMO, French GETUG group, Oncodistinct group, and also serves on the RCC committee within the French Association of Urology.
Kate Smith, MBBS, MRCP, MD, PhD
Guy’s and St Thomas
NHS Foundation Trust
London, UK
Kate Smith is currently the consultant Medical Oncologist at Guy’s and St Thomas NHS Foundation Trust in London, UK. She graduated from University College London in 2006 after completing a degree in Natural Sciences at the University of Cambridge. In 2010, she was appointed as a National Institute of Health Research Academic Fellow in Medical Oncology and received her training at St Bartholomew’s Hospital and the Royal Free NHS Trusts. She completed her PhD at Bart's Cancer Institute, focusing on hypoxic deregulation in clear cell renal cell carcinoma, and obtained her PhD degree in 2019.
Dr. Smith was appointed a Locum Consultant at the Royal Free NHS Trust in Genitourinary Oncology in 2020 and to a permanent position at Guy’s and St Thomas in 2022. She manages all urological malignancies with a focus on urothelial and prostate cancers. She is also the joint lead for urothelial cancer management.
The proposed initiative is specifically designed for medical oncologists, urologists, and other healthcare professionals involved or interested in the management of urothelial cancer.
Upon completion of this educational activity, participants should be able to:
- Identify how to sequence available options for second-line (2L) and salvage treatments of unresectable LA/m UC
- Establish confidence and expertise in selecting optimal strategies for sequential treatment of unresectable LA/m UC
- Develop strategies for the prevention and management of adverse events (AE) associated with the range of treatments used in unresectable LA/m UC
This educational activity is provided by ACE Oncology.
This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.
The Faculty of Pharmaceutical Medicine has approved this event for continuing professional development (CPD) and allocated it 2 CPD credits.
This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve the competence and performance of learners in order to improve patient care.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Aristotelis Bamias has served as an advisor or consultant for BMS, IPSEN and MSD. He has also served as a speaker or a member of a speakers bureau for BMS and Merck. In addition, he has received grants for clinical research from BMS, IPSEN, Pfizer and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Philippe Barthelemy has served as an advisor or consultant for Astellas, Astra Zeneca, BMS, Cilag, Eisai, IPSEN, Janssen, Merck, MSD, Novartis and Pfizer. He has also served as a speaker or a member of a speakers bureau for Astra Zeneca, BMS, Eisai, IPSEN, Merck, MSD and Pfizer. In addition, he has received grants for clinical research from BMS and IPSEN. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Kate Smith has served as a speaker or a member of a speakers bureau for Astellas and Bristol Myers Squibb. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of ACE Oncology have disclosed no relevant financial relationships.
ACE Oncology requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.